Plus, activity in the U.S. services sector accelerated in February, GE said the coronavirus will impact Q1 earnings, and Arcturus Therapeutics shares are on the rise after the company joins the quest to find a COVID-19 vaccine.
Read MoreBuy Target – $21.00 or better Sell Target – TradersPro Sell Signal Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate […]
Read MorePlus, manufacturing activity slumped in February, and Costco could see a sales boost from the coronavirus.
Read MoreBuy Target – $11.00 or better Sell Target – TradersPro Sell Signal Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management […]
Read MoreAnd the news has sent its stock soaring 60% higher.
Read MorePlus, Home Depot and Macy’s topped earnings estimates, while Shake Shack disappointed.
Read MorePlus, Warren Buffett called Apple “the best business I know in the world,” Intuit is buying Credit Karma, and Walls Fargo has agreed to pay $3 billion to settle the criminal and civil cases against it.
Read MoreThese 3 stocks are the ones to buy now in the biotech space, according to Citi analyst Mohit Bansal.
Read MoreOne analyst says this small diagnostics firm has demonstrated its ability and is now a Buy.
Read MorePlus, the Fed is monitoring the coronavirus outbreak’s impact on the global economy, Victoria’s Secret is going private, and Domino’s delivered an earnings beat.
Read MorePlus, Citi says gold could hit $1,700 per ounce in the next 6 – 12 months, Tesla shares topped $930, and one speculative space stock has seen its trading volume explode.
Read MoreThis drugmaker has a promising treatment for the virus and one expert says the stock’s technical picture makes it a buy now.
Read MoreTrade Setup Buy Target $59.48 Sell Target $65.02 CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It […]
Read MorePlus, the coronavirus finally has a name, Carnival Cruise Line said that the virus outbreak could dent full-year earnings, and Nissan is suing former Chairman Carlos Ghosn.
Read MorePlus, Fed Chairman Jerome Powell said the central bank is “closely monitoring” the effects of the coronavirus outbreak, and Under Armour shares are sinking after athletic apparel maker said it expects low-single digit sales growth this year.
Read More